Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Self-citationGershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
“Moreover, adjuvant therapy with new agents has shown impressive ability to improve clinical outcomes in patients with resected stage III melanoma.(22-24) It is against this background that the AJCC appointed a Melanoma Expert Panel to undertake the task of revising the cutaneous melanoma staging system for the eighth…”
BackgroundSelf-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Self-citationCancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Immune checkpoint inhibitors in melanoma
Carlino, M. S., Larkin, J., & Long, G. V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01206-x · Cited by 1,185
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
“In surgically resectable metastatic melanoma (stages IIIA to IV), randomized phase 3 clinical trials demonstrated the efficacy of adjuvant anti– PD-1 therapy, leading the FDA to approve nivolumab and pembrolizumab for this indication (8, 9).”
BackgroundImmune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Self-citationWeber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02268-7 · Cited by 916
Self-citationNeoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Self-citationThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Guidelines of care for the management of primary cutaneous melanoma
Swetter, S. M., Tsao, H., Bichakjian, C. K., Curiel-Lewandrowski, C., Elder, D. E., Gershenwald, J. E., Guild, V., Grant-Kels, J. M., Halpern, A. C., Johnson, T. M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.08.055 · Cited by 727
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
“Additionally, results from CheckMate 238 suggest that nivolumab had benefits for stage IV no evidence of disease (NED) similar to those of stage III, making it a clear option for this patient population [56].”
Self-citationKeung, E. Z., & Gershenwald, J. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1489246 · Cited by 593
“Major advances in the treatment options with the introduction of molecularly targeted and immunotherapies have resulted in improved survival for patients with locoregionally advanced and metastatic melanoma [2–5], and more recently for patients in the adjuvant setting [6,7].”
BackgroundNeoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402604 · Cited by 542
Self-citationImmune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Self-citationThe foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Advances in cancer immunotherapy 2019 – latest trends
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 563
Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30494-0 · Cited by 537
Self-citationRozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationApplication of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
“%* vs. 68.4%# vs. 58.2% (p b 0.005) KEYNOTE-006 phase 3 (n = 834) notherapy ilimumab or olumab) Median PFS: 11.5 vs. 6.9 vs. 2.9 months (p b 0.0001); ORR: 50% vs. 40% vs. 14% CheckMate-067 phase 3 (n = 945) limumab 12-month RFS: 70.5% vs. 60.8%; 16-month RFS: 66.4% vs. 52.7% (p b 0.0001) CheckMate-238 phase 3 (n = 906…”
BackgroundInfluentialLuke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., Long, G. V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00562-1 · Cited by 499
Self-citationMelanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Gershenwald, J. E., & Scolyer, R. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6513-7 · Cited by 452
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T., Kluger, H. M., Thomas, S. S., Domingo-Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 451
“In addition, patients recurring with advanced melanoma after adjuvant anti–PD-1 therapy for high-risk disease represent an emerging unmet need.(20-22)”
BackgroundSelf-citationMenzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Self-citationEndocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 436
Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Khattak, A., Carlino, M. S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5570 · Cited by 429
Self-citationFive-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005493 · Cited by 408
“Completion lymphadenectomy was part of the inclusion criteria for all three pivotal trials of current standard-of-care adjuvant therapies.(6,7,11) However, based on the results of the Multicenter Selective Lymphadenectomy Trial II (MSLT-II) and the German Dermatologic Cooperative Oncology Group (DeCOG) trial, relevant…”
BackgroundMethodSelf-citationSignal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
“In 2017, adjuvant anti-PD-1, nivolumab, showed longer RFS and lower rates of high-grade adverse events than adjuvant with ipilimumab among patients with resected stage III or IV melanoma in a phase III trial, Checkmate 238.(568) Comparisons of another anti-PD-1, pembrolizumab with placebo also showed improved efficacy…”
BackgroundEggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00065-6 · Cited by 387
Self-citationImmune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. (2018) · Chest · doi:10.1016/j.chest.2018.08.1048 · Cited by 379
Simonaggio, A., Michot, J. M., Voisin, A. L., Le Pavec, J., Collins, M., Lallart, A., Cengizalp, G., Vozy, A., Laparra, A., Varga, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1022 · Cited by 381
“37), time to initial irAE (5 [1-40] treatment cycles vs 3 [1-22] treatment cycles; P = .”
BackgroundRecent Advances in the Treatment of Melanoma
Curti, B. D., & Faries, M. B. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2034861 · Cited by 386
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312695 · Cited by 346
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
“Single-agent immunotherapy with the CTLA4-targeted blocking antibody ipilimumab 13,14 or the PD1-targeted blocking antibody nivolumab 15–19 was first approved for the treatment of patients with metastatic melanoma in 2011 and 2014, respectively.”
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 335
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Swetter, S. M., Thompson, J. A., Albertini, M. R., Barker, C. A., Baumgartner, J., Boland, G., Chmielowski, B., DiMaio, D., Durham, A., Fields, R. C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0018 · Cited by 340
Treatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
“In 2017, the Checkmate-238 study demonstrated improved RFS with nivolumab (antiePD-1) compared with ipilimumab and with a more favorable toxicity profile (Weber et al., 2017).”
BackgroundConstantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01211-7 · Cited by 336
Self-citationTalimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
Safa, H., Johnson, D. H., Trinh, V. A., Rodgers, T. E., Lin, H., Suarez-Almazor, M. E., Fa’ak, F., Saberian, C., Yee, C., Davies, M. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0774-y · Cited by 312
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000398 · Cited by 291
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
Self-citationMamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 283
Self-citationEggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02110 · Cited by 288
“gov identifier: NCT02388906) nivolumab trial was conducted in patients with stage IIIB-C and completely resected stage IV melanoma.(6) ASSOCIATED CONTENT Data Supplement Protocol”
BackgroundSelf-citationPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
“(195) Phase 3 CheckMate 238 trial in 906”
BackgroundPathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
Tetzlaff, M. T., Messina, J. L., Stein, J. E., Xu, X., Amaria, R. N., Blank, C. U., van de Wiel, B. A., Ferguson, P. M., Rawson, R. V., Ross, M. I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy226 · Cited by 284
Self-citationHack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 281
“65; however, survival results have not yet been reported (59).”
BackgroundSystemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 265
Self-citationImmunotherapy in Melanoma: Recent Advances and Future Directions
Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023) · Cancers · doi:10.3390/cancers15041106 · Cited by 256
Checkpoint inhibitor immunotherapy in kidney cancer
Xu, W., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 261
Self-citationPatrinely, J. R., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0051 · Cited by 253
Self-citationHauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01219 · Cited by 256
Self-citationKirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J.-J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02583-2 · Cited by 239
“…resected stage IIB/C disease was similar to that observed in patients with resected stage III or stage IV disease, including time to onset and time to resolution of immune-mediated adverse events, and was similar to that in pembrolizumab-treated patients with resected stage IIB/C disease 8,12 .”
Self-citationZimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F., Mohr, P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30417-7 · Cited by 243
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambiase, A., de Vincentiis, M., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 244
“The ECOG 6134 study is a randomized phase III trial comparing Ipilimumab plus Nivolumab followed by Dabrafenib plus Trametinib versus Dabrafenib plus Trametinib followed by Ipilimumab and Nivolumab in patients with advanced melanoma.”
InfluentialElkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Couey, M. A., Bell, R. B., Patel, A. A., Romba, M. C., Crittenden, M. R., Curti, B. D., Urba, W. J., & Leidner, R. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0645-6 · Cited by 243
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Systemic Therapy for Melanoma: ASCO Guideline Update
Seth, R., Agarwala, S. S., Messersmith, H., Alluri, K. C., Ascierto, P. A., Atkins, M. B., Bollin, K., Chacon, M., Davis, N., Faries, M. B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01136 · Cited by 224
“Of these, only three reported on therapies that were relevant to the recommendations: European Organisation for Research and Treatment of Cancer (EORTC) 18071,(61-63) EORTC 1325/KEYNOTE-054,(9) and CheckMate 238.(10) The remainder investigated IFN therapy or other therapies that are no longer relevant to recommendatio…”
MethodSelf-citationKeilholz, U., Ascierto, P. A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C. U., Chiarion Sileni, V., Donia, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.004 · Cited by 235
Self-citationWeinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 234
Macrophages and microglia: the cerberus of glioblastoma
Buonfiglioli, A., & Hambardzumyan, D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01156-z · Cited by 238
“As nivolumab and pembrolizumab have shown successful outcomes when administered as adjuvants in melanoma [128, 129], researchers aimed at looking in this direction for GBM.”
BackgroundLearning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Self-citationCutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Amaral, T., Ottaviano, M., Arance, A., Blank, C., Chiarion-Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J. E., Gogas, H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.006 · Cited by 206
“In the CheckMate 238 trial, 23 which compared nivolumab with ipilimumab 10 mg/kg in patients with AJCC7 stage IIIB, IIIC or IV resected melanoma, the 5-year RFS rates were 50% in the nivolumab group and 39% in the ipilimumab group (HR 0.72, 95% CI 0.60-0.86).”
InfluentialSelf-citationAge-Specific Incidence of Melanoma in the United States
Paulson, K. G., Gupta, D., Kim, T. S., Veatch, J. R., Byrd, D. R., Bhatia, S., Wojcik, K., Chapuis, A. G., Thompson, J. A., Madeleine, M. M., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3353 · Cited by 229
Self-citationRadiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite”
Arina, A., Gutiontov, S. I., & Weichselbaum, R. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2034 · Cited by 233
“org Clin Cancer Res; 26(12) June 15, 2020 2779”
BackgroundInfluentialChen, L.-T., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., Yeh, K.-H., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-019-01034-7 · Cited by 230
Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00097-8 · Cited by 221
Self-citationMelanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Rabbie, R., Ferguson, P., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2019) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 217
Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30332-8 · Cited by 218
Self-citationAdvancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
“However, scientists observed that patients with heterozygous germline mutations in CTLA-4 (in human) and Ctla-4 (in animals) knockout mice always exhibited severe immune dysregulation [35, 36], and many oncologists also observed that anti-CTLA-4monoclonal antibodies (mAbs) frequently induced autoimmune reactions in pa…”
Background
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.